Living with Lupus

Benlysta as an Add-On Treatment: German Cohort

Previous Article Next Article

New research examines belimumab, better known by the brand name, Benlysta, as an add-on therapy for people with lupus.

Researchers in Germany conducted an observational study of Benlysta use in the real world as an add-on treatment for lupus (SLE). After using Benlysta for 6 months, 78% of people experienced at least a 20% improvement in overall disease activity based on physician judgements. And, 42% experienced great benefit of the drug, defined as over a 50% improvement in physician analysis. Additionally, people were able to use fewer corticosteroids while using Benlysta and decreased unexpected use of health services like the ER.

Just published in the December 2016 issue of Rheumatology and Therapy, the results of the OBSErve Germany study mirror previous studies in the United States and Spain. OBSErve is a multinational study program funded by GlaxoSmithKline, the makers of Benlysta.

water-benlysta-lupus

Benlysta: A quick overview

Belimumab (Benlysta) is a new type of medication called a biologic. Biologics are made up, or derived from, living organisms. Benlysta is a specific human monoclonal antibody that is able to inhibit B cells, which are linked to responses by the immune system.

Benlysta was approved by the FDA in 2011, but there were a number of reservations about the drug. The FDA had concerns that:

  1. improvements measured using the SELENA-SLEDA scale were only marginal
  2. the belimumab treatment groups had more deaths than controls (including three suicides);
  3. participants of African or African-American descent did not significantly respond to the drug; and
  4. there were high numbers of adverse events in the trials

Subsequent studies, including these OBSErve studies, aim to answer some of these concerns raised during the approval process.

lupus-benlysta-ropes

Study Methodology

The OBSErve study was a retrospective, observational cohort study. That means that researchers analyzed health records to see how patients in the real world were responding to Benlysta based on common health indicators like SELENA/SLEDAI scores. Patient records were collected from 6 months prior to the start of Benlysta to 6 months after the start of Benlysta.

Results

78% of patients experienced a 20% or greater increase in overall clinical response as assessed by their physicians

Physician-Assessed Patient Improvement After 6 Months on Belimumab

  • Participants (n=96)

Additionally, objective measures of patient disease status, such as the SELENA/SLEDAI were used to measure common clinical and serological symptoms of lupus.

In total, SELENA/SLEDAI scores decreased from 10.6 to 5.6 in the first 6 months of treatment. The reduction means that the disease was less symptomatic following the start of Benlysta.

Researchers also looked into 6 specific symptoms of lupus: arthritis, fatigue, rash, alopecia, low complement, and increased anti-dsDNA antibody levels. The great majority of patients experienced an improvement to some or all of these symptoms. There was notable improvement of arthritis and rashes. The full report of improvement or worse outcomes by symptom is available here.

Patients receiving belimumab therapy for six months were also able to switch to low dose corticosteroid doses. Low dose treatment is understood to be under 7.5 mg/day of corticosteroid. Typical patient corticosteroid use decreased from 13.7 mg to 7.6 mg; those on high doses of corticosteroids dropped from 17.5 to 8.6 mg after Benlysta treatment.

Corticosteroid Use in Participant Sample

  • Low Dose (< 7.5 mg/day)
  • High Dose (Over 7.5 mg/day)
  • No Steroid Intake

Other findings of note

6 patients of 102 in the study discontinued treatment of Benlysta during the six months. For 3 of them, the physician-documented discontinue reason was “disease progression” and “ineffective medication.” 1 patient had an allergic reaction – which is consistent with previous findings that approximately 1% of people are allergic to belimumab. Also, one patient passed away, but “no causal relationship to belimumab was suspected.”

There were interesting finding regarding the number of visits per patient to the clinic, hospital, and emergency room as well. While the number of scheduled visits increased per patient so that people could receive their infusions, the number of unscheduled visits decreased overall. That means that there were fewer hospitalizations and ER visits following the start of Benlysta therapy. The full chart if available here.

Unscheduled Health Visitis

  • SLE-related ER visits
  • 2 or More Hospitalizations
  • 1 Hospitalization
  • 0 Hospitalizations
anchor-door-benlysta

Participant Profiles

For a full view of baseline patient profiles, click here

102 patient records were collected from 21 sites in Germany in 2013

91% of the participants were female

101 of the participants were Caucasian

Average age of participants was 42.5 years old (with a standard deviation of plus/minus 13.83 years

Average body mass index (BMI) was 25.3 kg/m^2 (standard deviation 6.19 kg/m^2)

85% of participants had Moderate or Severe SLE as determined by disease indices like the SELENA/SLEDAI.

58% of participants had been diagnosed with SLE for over 10 years

 

Why start Benlysta?

88% of participants started Benlysta because the previous treatments were not effective. And, 61% of people had lupus that was getting worse.

In only 26% of people was Benlysta added because the prior treatment regimen was not tolerated well by participants.

Lupus Manifestations and Co-Morbidities at Benlysta Start

  • Percentage of Participants
Comments (2)

2 thoughts on “Benlysta as an Add-On Treatment: German Cohort

  1. I have been using Benlysta for 2 years and it has significantly helped with my joint pain and inflammation. It is a miracle!

  2. I began using Benlysta in June of 2016. I did not begin to feel any significant results until the end of December 2016. I was diagnosed with Lupus 5 years ago. I noticed that this was the first time in 5 years that I didn’t wind up in the hospital. Prior years before, it seemed I always wound up in the hospital every December and February for debilitating muscle and joint pain, migraine, and fatigue. In November of 2016 I could barely walk. I had a cane for support. This year I’m walking without a cane, and my flares don’t seem to be as intense.

    In January 2017, I did go to the emergency room for off the chart joint pain, but was not admitted. In February I was in the emergency room for debilitating chest pain. I’d had these pains before off and on over the past five years, but never knew what or why. The ER doctor said I had Pleurisy, something common with people who have Lupus. I was given an injection for pain, and a prescription for a muscle relaxant.

    For the most part I still have the same Lupus symptoms, but not as severe. I’m not sure if the Benlysta or the Lupus has caused my hair to fall out more, thin out my eye brows, under arm hair, and pubic hairs. I still have the rash during flare-ups, but not as severe. The fatigue is the only thing that hasn’t changed much. I haven’t had mouth sores in a while, but during flares the sores and pimples return.

    Benlysta has made me feel better overall. I’m grateful for this medication.

Leave a Reply

Your email address will not be published. Required fields are marked *

Medications

Interferon, Lupus Research, & More: An Interview with Dr. Mary Crow

New treatments, laboratory tests, and digital technologies (not to mention a deeper understanding of...

Day-to-Day Living

Calorie-Restricted Diets, Healthy Eating, and Lupus

Diet can have a major impact on how we feel and is a crucial...

Day-to-Day Living

Air Quality and Lupus: Take a Deep Breath

Many Lupus Warriors are aware of the link between lupus and lung health, but...